FDA Approves Johnson & Johnson Psoriasis Drug ICOTYDE
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has approved ICOTYDE (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and …
FDA Approves Johnson & Johnson Psoriasis Drug ICOTYDE Read More